All In Biotech

NDA 022466 · Pierrel

Orabloc

Articaine Hydrochloride, Epinephrine Bitartrate · Injection

Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Feb 26, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

109

13 Phase 3, 2 recruiting

FAERS reports

180

76 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 27, 2026.

Articaine HCl and Epinephrine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older. Articaine HCl and Epinephrine is a combination of articaine HCl, an amide local anesthetic, and epinephrine, a vasoconstrictor, indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older ( 1 ).

Mechanism: Articaine HCl is an amide local anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Epinephrine is a vasoconstrictor added to articaine HCl to slow absorption into the general circulation and thus prolong maintenance of an active tissue...

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ORABLOC · ARTICAINE HYDROCHLORIDE 4%; EPINEPHRINE BITARTRATE EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML) · INJECTABLE, INJECTION · Prescription
  • ORABLOC · ARTICAINE HYDROCHLORIDE 4%; EPINEPHRINE BITARTRATE EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Articaine" as an intervention, any sponsor and status, largest first.

All 109 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective56
  • dizziness10
  • loss of consciousness9
  • hypoaesthesia oral8
  • paraesthesia8
  • therapeutic product effect prolonged8
  • anaphylactic shock7
  • drug effect prolonged7
  • nausea6
  • pain6
  • drug effect incomplete5
  • hypoaesthesia5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20102
20111
20123
20144
20155
20169
201725
20187
201915
202016
202110
202210
202326
202424
202517
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 306 on PubMed

Sponsor: Pierrel

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.